Product Description: Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection[1][2][3].
Applications: COVID-19-anti-virus
Formula: C14H20FN5O
References: [1]Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12./[2]Benjamin Ryan. Selgantolimod Shows Promise as Treatment for Hepatitis B. November 18, 2019./[3]Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment of hiv. US20170071944A1.
CAS Number: 2004677-13-6
Molecular Weight: 293.34
Compound Purity: 98.23
Research Area: Infection
Solubility: DMSO : 62.5 mg/mL (ultrasonic)
Target: HBV;Toll-like Receptor (TLR)
Deutsch
English
